The FCF Life Sciences Venture Capital Monitor – Europe is a monthly published overview of biotechnology, pharmaceutical, medical technology and healthcare technology companies, displaying Venture capital financing trends in the European Life Sciences industry.
As of the end of April 2023 we identify the following current VC trends in Europe:
- In 2023, overall Life Sciences funding has reached EUR 2,446m
- Top 5 Deals exceed EUR 90m each, largest transaction amounted to EUR 138m in Distalmotion (Switzerland)
- Revival Healthcare Capital (United States) dominates the Top 5 Investors (by deal volume), followed by Novo Holdings (Denmark) and Gilde Healthcare Partners (Netherlands)
- Biotech received 53% of the total investment volume (+3% compare to the previous month)
- Oncology dominates as the top indication in Biotechnology
Capital Markets Research
We constantly engage in capital markets research to identify financing trends early in the Life Sciences sector. Our research focuses on the most relevant equity markets: Venture Capital, Public Equity, Initial Public Offerings (IPO). The findings are currently published in the following publications:
Venture Capital
Licensing
Life Sciences Venture Capital Monitor – Europe
Monthly Venture capital activities in the European Life Sciences sector
Biotech Venture Capital Monitor – USAMonthly Venture capital activities in the US Life Sciences sector
Life Sciences Venture Capital ReportRecent Venture capital trends in the European Life Sciences sector
Other Research
Life Sciences IPO ReportRecent IPO trends in the Life Sciences sector
Biotech Public Equity MonitorRecent valuations of listed European Life Sciences companies
MedTech & Diagnostics Public Equity MonitorRecent valuations of listed MedTech companies
Life Sciences SPAC MonitorPerformance overview of merged Life Sciences SPACs
NEWS
Life Sciences Venture Capital Monitor – Europe 04/2023 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 04/2023”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences
FCF Biotech Venture Capital Monitor – USA 03/2023 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 03/2023”. The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector. As
Life Sciences Venture Capital Monitor – Europe 03/2023 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 03/2023”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences
Life Sciences Venture Capital Monitor – Europe 02/2023 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 02/2023”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences
Life Sciences Venture Capital Monitor – Europe 01/2023 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 01/2023”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences
